Note 10 - Net Loss Per Share

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 10. Net Loss per Share

The Company’s outstanding Series X Convertible Preferred Stock, Series B Convertible Preferred Stock, and warrants to purchase common stock have participation rights to any dividends that may be declared in the future, such that they are participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. All common share and per-share amounts for all periods presented reflect the Company’s 1-for-19 reverse stock split effective on August 15, 2025.

As a result of the net loss attributable to Catheter Precision, Inc.'s common stockholders for all periods presented herein, the following common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the three and nine months ended September 30, 2025 and 2024 because including them would have been antidilutive:

	September 30,
	2025	2024
Warrants for common stock	1,078,943	634,509
Employee stock options	164,355	5,026
Series B Convertible Preferred Stock	335,213	-
Series X Convertible Preferred Stock	66,610	66,610
Restricted stock awards	6,000	-
Total common stock equivalents	1,651,121	706,145

The weighted-average number of common shares outstanding as of  September 30, 2025 includes 16,550 shares of common stock sold under the ATM Agreement on September 30, 2025 but issued on October 1, 2025. Since these shares of common stock are issuable for no consideration and do not contain any other conditions that must be satisfied by the holder to ultimately receive such shares of common stock, these shares were included in the weighted-average number of common shares as of September 30, 2025.